drugset / Trial / NCT06228560
Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment
RandomizedParallel-groupTriple-blindTreatment
Summary
The study is a Phase II, multicenter, randomized, double-blind study to evaluatethe efficacy and safety of LP-003 administered subcutaneously as an add-on therapy for the treatment of adult patients aged 18-75 who have been diagnosed with refractory CSU and who remain symptomatic despitestandard-dose H1 antihistamine treatment.
Timeline
- Start
- 2024-01-26
- Primary completion
- 2025-04-17
- Completion
- 2025-11-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LP-003 | Unknown | — | Subcutaneous |
| Comparator | Omalizumab | Monoclonal antibody | 300 mg | Subcutaneous |